Please assess the completion status of the following clinical trial:

Trial Title: Covid-19, Hospitalized, PatIents, Nasafytol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult ≥ 18 years of age at the time of inclusion in the study;~* Recently hospitalized patients in whom SARS CoV-2 infection has been laboratory confirmed by RT-PCR or other commercial or public health test on any sample.~* Severity of 3-4-5 according to the WHO 7-point ordinal scale (3: hospitalized, no oxygen therapy; 4: hospitalized, oxygen by mask or nasal prongs; 5:non-invasive ventilation or high-flow oxygen);~* Subject (or authorized legal representative) who can provide oral or written informed consent before beginning any study procedure;~* Understand and agree to abide by the study procedures.~Exclusion Criteria:~* Contra-indication to NASAFYTOL® or constituents (incl. Vit D): hypersensitivity or allergy to product components;~* Swallowing disorder or inability to take oral caps;~* Presence of comorbidities that imply a poor prognosis (according to clinical judgment);~* Pregnancy or breastfeeding women; If patient is a female of childbearing potential, patient must use an effective means of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined hormonal contraceptives or intrauterine devices or sexual abstinence);~* Serious or active bacterial infections or documented sepsis by pathogens other than SARS-CoV-2;~* Patients participating in clinical trials of other products; Patients presenting acute impairment of renal function or nephrolithiasis; ALT/AST\> 5 times the normal limit, or Neutropenia (Absolute neutrophil count \< 500/uL), or Thrombocytopenia (Platelets \< 50,000/uL).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard treatment + NASAFYTOL® (Type: EXPERIMENTAL): Minimum 25 patients will receive NASAFYTOL® as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19.~For each patient, 8 capsules of NASAFYTOL® taken orally per day (4 capsules in the morning and 4 capsules in the evening before meal ,with a full glass of water. ) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and during the period of hospitalization and maximum for 14 days
- standard treatment + FULTIUM® - D3 800 (Type: ACTIVE_COMPARATOR): Minimum 25 patients will receive vitamin D , FULTIUM® - D3 800 as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19.~For each patient,1 capsule of Vitamin D taken orally per day (1 capsule in the morning) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and for the duration of the hospitalization and maximum for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).